Big Pharma slammed for executive payouts that nearly matched R&D budget

Twenty of the world’s largest pharmaceutical companies made payouts to their executives and shareholders that almost equaled the money they spent on research and development between 2020 and 2022, according to a new analysis that the People’s Vaccine Alliance released ahead of this week’s World Health Summit in Berlin.

At the same time, pharmaceutical companies and allied governments maintain that they cannot allow for waivers on the intellectual property and trade secrets for new vaccines and therapeutics during future pandemics because it will discourage innovation.

Activists argue that with profits large enough to afford these levels of payouts, which they estimate at $1 million every five minutes, there is room for more flexibility around IP, which they believe could ultimately spur broader production and accessibility in a future pandemic. They are hoping the figures will impact ongoing debates within the World Health Organization over a global pandemic treaty.

Read more.


Soda industry playbook on display in South Africa's sugar tax battle

Over the past decades, South Africa has experienced soaring rates of obesity and the non-communicable diseases it contributes to, including diabetes, high blood pressure and heart disease. Health experts blame that rise, in part, on an overconsumption of sugar. Sweetened beverages are a prime delivery mechanism. 

Models show that in the long run, sugar taxes can bring down obesity rates. 

While public health experts celebrated the adoption of the levy in South Africa, their enthusiasm was tempered by a fierce fight that led to a weaker law than they wanted, and are concerned by recent signs that the country’s powerful sweetened-beverage manufacturers are trying to undermine it. 

Read more.


The path to universal access

South Africa is currently mired in a deeply inequitable two-tiered health system. An underregulated private sector serves a minority of the country but employs nearly 80 percent of its doctors and specialists. The rest of South Africa—roughly 50 million people—relies on an overstretched, understaffed public system.

As early as next year, a new law could refashion private health services and advance universal health care. So why is it so unpopular? Read more.